Compare Amgen, Inc. (AMGN) vs Simon Property Group Inc (SPG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Simon Property Group Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Simon Property Group Inc trades at $218 (market cap $70.94B). The key difference: Amgen, Inc. is far larger — about 2.8× Simon Property Group Inc's market cap, and Simon Property Group Inc pays the higher dividend (4.02%). Which is the better fit depends on your goals.
| AMGN | SPG | |
|---|---|---|
Market Cap | $196.12B | $70.94B |
Sector | Health | Real Estate |
52-Week High | $388.16 | $227.56 |
52-Week Low | $271.18 | $159.93 |
Enterprise Value | $241.41B | $99.42B |
Dividend Yield | 2.77% | 4.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Simon Property Group (SPG) trades at $218.77, down 0.43% on the day, with a bullish technical signal from moving averages. The REIT shows strong profitability with a 70.59% net income margin and has beaten earnings estimates in three consecutive quarters. Recent news highlights robust Q1 2026 results and a dividend payout of $2.25 for H1-26.
Outlook remains positive due to strong leasing and redevelopment, but risks include high debt levels and e-commerce competition. Analyst consensus is mixed with a $214.40 price target, slightly below current levels, suggesting cautious optimism amid solid fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
